Admission of Ordinary Shares

29 September 2015

Instem plc
("Instem" or the "Company")

Admission of Ordinary Shares

Further to the Company’s announcement dated 3 August 2015 in relation to the third earn out payment in respect of the acquisition of Logos Holdings Limited, which included £650,000 by way of the issue and allotment of ordinary shares of 10 pence each in the capital of the Company ("Ordinary Shares"), Instem confirms that application has been made for the 339,586 Ordinary Shares to be admitted to trading. Admission is expected to be effective at 8.00 a.m. on 11 August 2015.

For further information, please contact:

Instem plc www.instem.com
Phil Reason, CEO +44 (0) 1785 825600
Nigel Goldsmith, CFO  
N+1 Singer (Nominated Adviser & Broker) +44 (0) 20 7496 3000
Richard Lindley  
Nick Owen  
James White  
Wallbrook Financial PR Tel: +44 (0) 20 7933 8000
Paul Cornelius or instem@walbrookpr.com
Sam Allen  
Helen Cresswell  
Paul Whittington  

About Instem

Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidlyexpanding needs of life science and healthcare organisations for data-driven decision making leading to safer, more effective products.

Instem’s portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.

Instem supports over 450 clients through full service offices in the United States, United Kingdom and China with additional locations in Japan and India.

To learn more about Instem solutions and its mission, please visit instem.com.